Introduction
============

Breast cancer is the most common cancer and leading cause of cancer death among women worldwide.[@b1-clep-4-011] Among Danish women, breast cancer accounted for 29% of all incident cancers, and was the cause of 16% of all cancer deaths among women during the period 1999--2006.[@b2-clep-4-011] To improve survival of Danish patients with breast cancer, nationwide biannual mammographic screening was introduced in 2007 and offered to women between 50 and 69 years of age.[@b3-clep-4-011] Cancer stage is an important predictor of prognosis, with 5-year survival of 98% for localized breast cancer decreasing to 27% for metastatic disease.[@b4-clep-4-011] Therefore, analyses of temporal changes in stage-specific incidence and mortality from breast cancer are important for evaluating the effectiveness of early detection and treatment programs.

Cancer registries are valuable resources for monitoring cancer incidence and survival. The Danish Cancer Registry (DCR) has recorded incident cases of cancer on a nationwide basis since 1943 and has been shown to have accurate and almost complete ascertainment of cancer cases. The International Classification of Disease revision 7 (ICD-7) was used until 2003 to categorize cancer sites, and has been converted to the International Classification of Disease revision 10 (ICD-10).[@b5-clep-4-011],[@b6-clep-4-011] The DCR includes information on diagnosis, cancer type, topography, morphology, and stage according to the Tumor, Node, Metastasis (TNM) classification.[@b7-clep-4-011] Information on TNM classification may be prone to underreporting and misclassification, eg, of tumor size (T) and lymph node (N) status.[@b8-clep-4-011] Missing information may potentially lead to biased results, if the missing information is not random. Thus, to draw valid inferences from stage-specific analysis, completeness needs to be quantified. Currently, there is a lack of studies on completeness of TNM classification in the DCR. Therefore, we conducted this study to evaluate completeness of TNM classification for breast cancer. In addition, we aimed to determine whether the completeness varied by gender, patient age, calendar period, cancer stage, or level of comorbidity.

Materials and methods
=====================

We performed this study in Denmark, which has about 5.4 million inhabitants. All residents are provided with free, tax-supported medical care. Since 1968, the Danish Civil Registration System has assigned a unique 10-digit personal identification number to all Danish residents,[@b9-clep-4-011] encoding date of birth and gender. This number is used in all Danish registers, allowing unambiguous individual-level data linkage.

Ascertainment of patients with breast cancer
--------------------------------------------

From the DCR, we identified all patients with a primary diagnosis of invasive breast cancer (ICD-10 code C50) between 2004 and 2009.[@b5-clep-4-011],[@b6-clep-4-011] Tumor stage was recorded as local, regional, or distant in the DCR until 2003.[@b5-clep-4-011] Since 2004, stage has been recorded using the TNM classification.[@b7-clep-4-011] From the DCR, we also obtained information on date of diagnosis, age, and gender.

Comorbidity
-----------

Data on the presence of comorbidity were obtained from the Danish National Patient Registry (DNPR).[@b10-clep-4-011] This registry contains data on all admissions to nonpsychiatric hospitals in Denmark since 1977 and outpatient contacts since 1995, including the personal identification number, date of admission/contact and discharge, and diagnosis codes (ICD-10 from 1994 and onwards). We defined pre-existing comorbidity using the Charlson Comorbidity Index (CCI), based on hospital diagnoses within 10 years preceding the date of breast cancer diagnosis. The CCI is based on disease categories which are each weighted according to the adjusted risk of one-year mortality.[@b11-clep-4-011] Excluding breast cancer, we defined the level of comorbidity as low (CCI score 0), medium (CCI score 1--2), and high (CCC score ≥3).

Statistical analysis
--------------------

We calculated the completeness and corresponding 95% confidence intervals, of the TNM registration overall, by each component individually (ie, T, N, and M), and according to the stage categories (see [Appendix](#t1-clep-4-011){ref-type="table"}). To reduce the prevalence of patients with breast cancer of unknown stage, we converted the TNM classification into summary staging using an algorithm that allowed categorization of tumors with certain missing TNM stage components into localized, regional, distant, and unknown stage (see [Appendix](#t1-clep-4-011){ref-type="table"}). Missing data were allowed if the information available on other T, N, or M components provided sufficient and meaningful information to stage the tumors. The "unknown" category represented tumors of high T class, which are known to have considerable risk of lymph node or distant metastasis, but lacked information of either or both.

Completeness was defined as the number of individuals with TNM recordings, and defined stage categories, divided by the total number of patients. We stratified completeness by gender, age (0--39 years, 40--59 years, 60--79 years, and ≥80 years), year of cancer diagnosis, and CCI score (low, medium, high). Analyses were performed using SAS (version 9.2; SAS Institute Inc, Cary, NC).

Results
=======

We identified 26,488 patients with incident breast cancer between 2004 and 2009. The median patient age was 63 years (interquartile range 54--72 years). A total of 26,350 (99.5%) breast cancer patients were women, and 138 (0.5%) were men.

The overall completeness of TNM registration was 85.4%. There was a slightly better registration for women than for men (85.4% versus 81.2%). There were no major changes in TNM completeness during the six-year study period, though completeness was slightly lower in 2009 compared with previous years. Completeness declined markedly with advancing age, from 91.3% among patients aged 0--39 years to 57.0% among patients aged 80 years and older. Completeness also declined with increasing CCI score, from 87.9% among patients with a low level of comorbidity to 69.7% among patients with high levels of comorbidity. Similar patterns were found for the individual components of the TNM classification, although the N and M recordings had somewhat more missing values than T. These data are presented in [Table 1](#t1-clep-4-011){ref-type="table"}.

Using the algorithm allowing inclusion of some Tx, Nx, and Mx codes in the classification of tumor stage ([Appendix](#t1-clep-4-011){ref-type="table"}) decreased the number of unknown tumors from 3867 when not allowing any x's in the definite stage categories to 2551 using the algorithm allowing some x's in these categories (data not shown). Thus, with our algorithm, the proportion of tumors with unknown stage was reduced from 14.6% to 9.6%. Similar to the primary analyses of TNM completeness, the proportion of tumors of unknown stage was highest among older patients and those with high CCI scores. The proportion of patients with localized breast cancer at the time of diagnosis increased from 43.2% in 2004 to 49.8% in 2009. These data are presented in [Table 2](#t2-clep-4-011){ref-type="table"}.

Discussion
==========

In this nationwide study, we found reasonable completeness of TNM registration in the DCR. The completeness was relatively constant during the study period, except for a slight decline from 2008 through 2009, which was due to a delay in the recording of TNM. However, we found that completeness varied substantially with patient age and level of comorbidity. When we applied a stage algorithm allowing some missing TNM components in the various categories, the proportion of cases with definite staging increased.

The main strengths of our study included the population-based design and use of nationwide data from the DCR, which has virtually complete ascertainment of breast cancer.[@b12-clep-4-011] However, we only examined completeness of TNM registration, and our study did not allow for estimation of the accuracy of TNM registration. Furthermore, the impact of classifying some unknown stage breast tumors into categories with known tumors may not be appropriate for all purposes.

Moreover, we may have misclassified comorbidity due to inaccuracy of hospital and outpatient diagnoses as well as lack of information on comorbidities diagnosed in primary care. Even so, a recent study reported consistently high positive predictive values for all of the CCI diseases based on diagnoses recorded in the DNPR.[@b13-clep-4-011]

Compared with other cancer sites, the proportion of unstaged breast cancer patients is typically relatively low,[@b8-clep-4-011] though other studies, in agreement with our findings, have shown declining completeness of TNM registration with increasing age and comorbidity score.[@b8-clep-4-011],[@b14-clep-4-011] In particular, Yancik et al[@b15-clep-4-011] found that women older than 70 years underwent fewer lymph node dissections than younger women. Other studies have also shown that elderly breast cancer patients and patients with comorbidity are less likely to receive breast cancer treatment according to treatment guidelines and have a poorer prognosis than younger patients with no severe comorbid conditions.[@b16-clep-4-011],[@b17-clep-4-011] The reasons are likely multifactorial, and may include less complete diagnostic assessment related to age, comorbidity and disabilities, patient preferences, apparent signs of distant metastases obviating the need for staging in treatment decisions, or competing medical conditions requiring treatment prior to cancer therapy. However, cautious interpretation of our results is necessary, as age and comorbidity are usually correlated.

TNM completeness does not necessarily reflect the clinical reality. For example, a breast cancer case who for various reasons was not treated surgically might be coded Nx, although axillary lymph node biopsy revealed positive lymph node metastases. As a second example, for breast cancer treated with curative intent surgery, no other diagnostic work-up other than a lung x-ray is performed. These cases are likely registered as M0 by most surgeons, although some might prefer to denote them as Mx.

Our findings may have important implications for studies using information on breast cancer stage. Because completeness was lower among the elderly and those with a high level of comorbidity, the data on TNM stage was not missing at random. Consequently, study results may potentially be biased when staging constitutes the exposure or a confounding factor, and this may lead to incorrect conclusions. Thus, patients with missing data on TNM stage should be carefully handled in the statistical analyses, eg, by applying missing imputation methods,[@b18-clep-4-011] or bias analysis.[@b19-clep-4-011] For instance, population-based cancer registry data is important for monitoring the effectiveness of mammography screening programs. Stage-specific analyses are especially crucial, and stage-recording practices may affect the evaluation of screening program and trends in stage-specific incidence and prognosis. However, most patients with screening mammography-detected breast cancer undergo surgery, and consequently have high TNM completeness.

In conclusion, our study showed that completeness of TNM registration for breast cancer varied differentially with age and level of comorbidity. Therefore, careful consideration should be given to the methodological implications in studies of cancer-related outcomes using data from the DCR.
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###### 

Algorithm for breast cancer staging according to the TNM classification

  ----------------- --------- ------- --------
  **Tumor stage**                     
  Localized         T1--4     N0      M0
                    T1--2     N0      Mx
                    T1        Nx      M0x
  Regional          T1--4,x   N1--3   M0
  Distant           Any T     Any N   M1
  Unknown           T2--4,x   Nx      M0--x
                    T3--4,x   N0      Mx
                    T1--4,x   N1--3   Mx
                    T0        N1--3   M0--1x
                    T0        N0,x    M1
  ----------------- --------- ------- --------

**Note:** There were six patients with T0 tumors (no evidence of primary tumor). These were all categorized in the unknown category.

**Abbreviation:** TNM, Tumor, Node, Metastasis.

###### 

Proportions and 95% confidence intervals for completeness of TNM registration among breast cancer patients in the Danish Cancer Registry by year of breast cancer diagnosis, gender, age group, and Charlson Comorbidity Index score

                          TNM completeness   T completeness   N completeness   M completeness   Total                                        
  ----------------------- ------------------ ---------------- ---------------- ---------------- ------- -------------- ------ -------------- --------
  Overall                 85.4               (85.0--85.8)     94.7             (94.4--94.9)     89.6    (89.2--90.0)   89.7   (89.3--90.1)   26,488
  **Year of diagnosis**                                                                                                                      
  2004                    86.0               (84.9--87.1)     94.7             (94.0--95.4)     89.3    (88.3--90.3)   91.0   (90.1--91.9)   3904
  2005                    86.6               (85.5--87.7)     95.6             (94.9--96.2)     89.8    (88.8--90.7)   92.1   (91.2--92.9)   3940
  2006                    84.8               (83.7--85.9)     95.8             (95.2--96.4)     90.0    (89.1--90.9)   89.9   (89.0--90.8)   4103
  2007                    85.9               (84.8--86.9)     96.0             (95.4--96.6)     90.5    (89.6--91.3)   90.9   (90.0--91.7)   4122
  2008                    87.0               (86.0--87.9)     95.4             (94.8--96.0)     91.3    (90.5--92.1)   90.4   (89.5--91.2)   4737
  2009                    82.9               (81.9--83.9)     91.6             (90.8--92.3)     87.4    (86.5--88.2)   85.5   (84.6--86.4)   5682
  **Gender**                                                                                                                                 
  Female                  85.4               (85.0--85.9)     94.7             (94.4--95.0)     89.6    (89.3--90.0)   89.7   (89.3--90.1)   26,350
  Male                    81.2               (74.0--87.0)     93.5             (88.4--96.7)     85.5    (78.9--90.6)   88.4   (82.3--92.9)   138
  **Age group (years)**                                                                                                                      
  0--39                   91.3               (89.5--93.0)     96.6             (95.3--97.6)     94.9    (93.4--96.1)   94.2   (92.6--95.5)   994
  40--59                  91.5               (90.9--92.0)     96.7             (96.3--97.0)     95.4    (95.0--95.8)   93.5   (93.0--94.0)   9740
  60--79                  87.3               (86.7--87.8)     94.9             (94.5--95.3)     91.2    (90.7--91.7)   91.3   (90.8--91.8)   12,632
  ≥80                     57.0               (55.3--58.8)     86.9             (85.7--88.1)     63.6    (61.9--65.3)   70.0   (68.4--71.6)   3122
  **CCI score**                                                                                                                              
  Low                     87.9               (87.5--88.4)     95.4             (95.1--95.7)     91.9    (91.5--92.3)   91.4   (91.0--91.8)   20,274
  Medium                  78.8               (77.7--79.9)     93.0             (92.2--93.6)     83.8    (82.8--84.8)   84.9   (83.9--85.9)   5100
  High                    69.7               (67.0--72.4)     89.2             (87.3--91.0)     74.5    (71.9--77.0)   80.7   (78.3--82.9)   1114

**Abbreviations:** CI, confidence interval; CCI, Charlson Comorbidity Index; TNM, Tumor, Node, Metastasis classification.

###### 

Proportions and 95% confidence intervals for staging of breast cancer patients in the Danish Cancer Registry by year of breast cancer diagnosis, gender, age group, and Charlson Comorbidity Index score

                          Cancer stage[a](#tfn3-clep-4-011){ref-type="table-fn"}                                                                                  
  ----------------------- -------------------------------------------------------- -------------- ------ -------------- ----- ------------- ------ -------------- --------
  Overall                 46.0                                                     (45.4--46.6)   39.2   (38.6--39.8)   5.2   (5.0--5.5)    9.6    (9.3--10.0)    26,488
  **Year of diagnosis**                                                                                                                                           
  2004                    43.2                                                     (41.7--44.8)   41.4   (39.9--43.0)   6.4   (5.6--7.2)    9.0    (8.1--9.9)     3904
  2005                    43.7                                                     (42.1--45.2)   42.3   (40.8--43.8)   6.0   (5.3--6.8)    8.0    (7.2--8.9)     3940
  2006                    45.2                                                     (43.7--46.7)   40.7   (39.2--42.2)   5.2   (4.5--5.9)    8.9    (8.1--9.8)     4103
  2007                    44.4                                                     (42.9--45.9)   41.4   (39.9--42.9)   5.8   (5.1--6.6)    8.3    (7.5--9.2)     4122
  2008                    47.5                                                     (46.1--48.9)   38.7   (37.3--40.1)   4.7   (4.1--5.3)    9.1    (8.3--10.0)    4737
  2009                    49.8                                                     (48.5--51.1)   33.2   (32.0--34.4)   3.9   (3.4--4.4)    13.1   (12.3--14.0)   5682
  **Gender**                                                                                                                                                      
  Female                  46.0                                                     (45.4--46.6)   39.2   (38.6--39.8)   5.2   (5.0--5.5)    9.6    (9.3--10.0)    26,350
  Male                    37.7                                                     (29.9--46.0)   43.5   (35.4--51.8)   7.2   (3.8--12.5)   11.6   (7.1--17.7)    138
  **Age group (years)**                                                                                                                                           
  0--39                   40.1                                                     (37.1--43.2)   49.3   (46.2--52.4)   4.0   (2.9--5.4)    6.5    (5.1--8.2)     994
  40--59                  45.8                                                     (44.8--46.8)   44.9   (43.9--45.9)   3.6   (3.3--4.0)    5.7    (5.3--6.2)     9740
  60--79                  48.5                                                     (47.6--49.3)   37.8   (36.9--38.6)   5.8   (5.4--6.2)    8.0    (7.5--8.5)     12,632
  ≥80                     38.2                                                     (36.6--40.0)   24.0   (22.6--25.6)   8.4   (7.4--9.4)    29.4   (27.8--31.0)   3122
  **CCI score**                                                                                                                                                   
  Low                     46.2                                                     (45.5--46.9)   40.8   (40.1--41.5)   4.9   (4.6--5.2)    8.1    (7.8--8.5)     20,274
  Medium                  46.2                                                     (44.9--47.6)   34.2   (32.9--35.5)   5.8   (5.2--6.4)    13.8   (12.9--14.8)   5100
  High                    40.4                                                     (37.5--43.3)   32.5   (29.8--35.3)   9.2   (7.7--11.1)   17.9   (15.7--20.2)   1114

**Note:**

Based on the staging algorithm ([Appendix 1](#t1-clep-4-011){ref-type="table"}).

**Abbreviations:** CI, confidence interval; CCI, Charlson Comorbidity Index; TNM, Tumor, Node, Metastasis classification.
